Attacking pathogens through their hosts by Kellam, Paul
Genome Biology 2006, 7:201
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
Review
Attacking pathogens through their hosts
Paul Kellam 
Address: Virus Genomics and Bioinformatics Group, Division of Infection and Immunity, University College London, London W1T 4JF, UK.
Email: p.kellam@ucl.ac.uk
Abstract
Through understanding the intricacies of host-pathogen interactions, it is now possible to inhibit
the growth of microbes, especially viruses, by targeting host-cell proteins and functions. This new
antimicrobial strategy has proved effective in the laboratory and in the clinic, and it has great
potential for the future.
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It is now clear that, despite the optimism of the 1967 US
Surgeon General in stating that ‘it’s time to close the book on
infectious diseases’, implying that drugs such as antibiotics
had made microbial diseases a thing of the past, infectious
diseases remain a major cause of continuing human suffer-
ing. It is estimated that infectious diseases currently account
for one third of global annual deaths. This led the more
recent 16th US Surgeon General, David Satcher, to state that
‘we are seeing a global resurgence of infectious disease’.
Finding ways to treat these diseases is a continuing battle,
and any new avenues for discovering therapeutics should
be explored. 
Current approaches to antimicrobial drug
development  
The paradigm of antimicrobial drugs, be they against
viruses, bacteria, fungi or parasites, has been to target
unique processes or enzymes of the pathogen with a specific
drug, thus achieving a high antimicrobial effect and low
host-cell toxicity because there is no cross-inhibition of host-
cell proteins. This paradigm has been used to develop almost
all current antimicrobial therapies, with many notable suc-
cesses, and it will continue to be an important drug-develop-
ment strategy in the future [1,2]. Even when pressure from a
drug results in the selection of drug-resistant variants, the
antimicrobial drug pipeline has delivered new therapies that
allow us to stay ahead - in some cases just ahead - of a resur-
gence of old microbial diseases [3]. 
Despite this success, it is clear that the pipeline of new
antimicrobial drugs is not full, and it may never be possible
to develop drugs targeted to all the diverse pathogens that
cause disease. This is partly because the disease burden of
any one pathogen is unlikely to reach sufficient levels for
pharmaceutical companies to justify the enormous cost of
developing a new drug, which (although hotly debated) is
estimated to be between $0.5 billion and $1.7 billion [4-6].
Although legislation over the past 20 years in the USA, espe-
cially the ‘Orphan Drug Act’, is designed to reduce such bar-
riers, the difficulty of developing new antimicrobial drugs
remains, and it is compounded by the fact that many infec-
tious diseases requiring treatment occur in developing coun-
tries, which cannot cope with the costs of new drugs. In
addition, the fact that multiple companies develop drugs
against the same ‘important’ pathogen dilutes an already
limited market share; this can be beneficial, however, when
drug combination therapy is used to reduce the selection for
drug resistance in, for example, human immunodeficiency
virus (HIV) in patients with acquired immune deficiency
syndrome (AIDS). 
Broad-spectrum antibiotics are a way to expand the number
of diseases that are treatable with the same medicine, but in
the field of antiviral drugs such broad-spectrum classes of
drug are less common. Even despite the massive sequencing
of microbial genomes, which has identified many new drug
targets, the classic antimicrobial paradigm cannot quickly
deliver what we need. Given that encounters with existing ornew microbial pathogens are unlikely to decrease [7], can we
find a new way of combating microbial disease? Evidence
suggests that we can, and that by using genome-scale
approaches to identifying critical host-cell functions that
facilitate microbial replication, we may be able to unlock
new potential in both existing and future drugs.
New approaches to antiviral therapy  
It is clear that all pathogenic microorganisms interact in
some way with host tissues and cells during the disease
process. These interactions can now be viewed at the level of
whole-genome transcriptional responses [8,9]. In the case of
viruses the interaction is obligatory, as viruses require the
host-cell environment to replicate. It is the viral world that
provides clues to how we could acquire a new range of
antimicrobial drugs at relatively little cost and on a short
timescale.
The concept of attacking the microbe by altering or aug-
menting a host-cell function or process is not new. The use
of interferon  (IFN) in combination with ribavirin in the
treatment of hepatitis C virus infection is successful in 50%
of infected individuals on a long-term basis [10,11], although
the exact mode of action, and the reasons why 50% of people
do not respond fully, are not understood. Similarly, inter-
leukin-2 (IL-2) has been used to augment ‘highly active anti-
retroviral therapy’ (HAART) in HIV infection (HAART is a
multiple drug combination therapy with higher antiviral
activity than therapy with a single drug). Although this does
not directly affect the viral load in the peripheral blood, it
accelerates the normalization of CD4+ T-cell counts in
infected individuals (HIV-infected individuals have reduced
numbers of T cells bearing the CD4 cell-surface molecule
because of the effects of HIV replication) [12].
Recently, however, a new anti-infective paradigm has
emerged, a logical extension of INF and IL-2 therapies but
more sophisticated. Because pathogens, especially viruses,
use host-cell pathways and enzymes for their replicative life
cycle, it seems reasonable to expect that inhibiting such cel-
lular processes would have an antiviral effect as a byproduct.
There is now ample evidence, both in vitro and in vivo, that
this is an effective strategy. Moreover, because all existing
licensed drugs that target a human disease process affect the
functioning of a cell or organ system in some way, we have in
effect a ready-made pharmacy of antimicrobial agents with
defined safety-data profiles and clinical-use histories that
only require assessment for new or ‘off target’ second use.
Inhibiting host-cell functions produces an antiviral
effect  
The evidence that the approach of inhibiting host-cell func-
tions works now extends across many diverse virus types,
including poxviruses [13], herpesviruses [14-16], retroviruses
[17], hepadnaviruses [18,19] and flaviviruses [20] (Table 1).
But how were these novel antiviral targets discovered? In
some cases, the insight came from basic knowledge of cellular
enzymes and pathways with which the viral proteins interact.
In other cases, genome-scale approaches such as gene-
expression profiling using DNA microarrays identified
genes, upregulated as part of the infected cell response, that
were also known targets for drugs. 
There are at least three possible functions of these upregu-
lated genes. First, they may be induced specifically by a
given virus to facilitate efficient virus replication. Second,
they may be induced as part of the cellular response to the
pathogen and cause disease pathogenesis. And third, they
may be part of the cellular response leading to pathogen
clearance. Targeting genes in the first and second categories
should lead to reduced virus replication and attenuated
disease pathogenesis, whereas inhibiting genes involved in
pathogen clearance should be avoided. 
The antiviral properties that have been described for Gleevec
(Imatinib mesylate), which was originally licensed for the
treatment of chronic myelogenous leukemia and inhibits the
Abl tyrosine kinase, exemplify the advantages of target dis-
covery that uses both basic knowledge and the genome-scale
approach. Knowledge that the protein A36R of the vaccinia
virus, a poxvirus, is phosphorylated by both Src and Abl
receptor tyrosine kinases led Reeves et al. [13] to examine
the effects of inhibiting A36R phosphorylation. It became
evident that Gleevec not only decreased virus titer and
plaque size in tissue culture, but also prevented the effects of
a lethal dose of vaccinia in a mouse nasal challenge assay,
showing that Gleevec had the potential to limit the spread of
vaccinia in vivo. 
For the Kaposi’s sarcoma herpesvirus (KSHV), infection of
endothelial cells in vitro results in a change in cellular mor-
phology from cobblestone-like to a spindle-cell appearance
reminiscent of Kaposi’s sarcoma (KS) cells. This was shown
by Moses et al. [14] to coincide with increased expression of
c-Kit, another target of Gleevec. Gleevec was tested and
shown to prevent this change in cellular morphology in vitro
[14]. More recently, the results of a small clinical study
showed that Gleevec also reduced tumor size in 50% of
people with KS [21]. 
An inhibitor of another KSHV-mediated cellular effect, B-cell
lymphoma development, was also identified through
changes in gene-expression patterns. My colleagues and I
[16] identified the vitamin D receptor as being highly
expressed in a subset of B-cell lymphomas, including KSHV
primary effusion lymphoma, and showed by using a vitamin
D receptor analog that the proliferation of these tumors
could be greatly reduced in vitro. Similarly, changes in gene
expression following human cytomegalovirus (HCMV) infec-
tion in vitro showed increased expression of cyclooxygenase
2 (COX-2) [22]. COX-2, a component of the prostaglandin
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thesis pathway, catalyzes the production of prostaglandin
H2 from arachidonic acid. Using COX-2 inhibitors, Zhu et
al. [15] went on to show that HCMV titer could be reduced
by two orders of magnitude in vitro. This result fits with the
fact that inhibitors of the eicosanoid pathway, such as
aspirin (a nonsteroidal anti-inflammatory drug that inhibits
COX-1 and COX-2), also inhibit HCMV replication [23]. The
importance of COX-2 to cytomegalovirus replication is high-
lighted further by the fact that the related rhesus
cytomegalovirus (RhCMV), which infects rhesus macaques,
encodes its own COX-2 ortholog [24]. Although the long-
term use of COX-2 inhibitors results in an increased risk of
cardiovascular toxicity in some individuals, a fact that has
resulted in the withdrawal of the drugs for treating arthritis,
it is possible that short-term use of the drug would be useful
and safe in the treatment of acute HCMV disease.
Two other approved drugs have shown promising effects in
the treatment of viral disease; in fact, they converge on a
common cellular pathway but affect different components
and different viruses (Figure 1). Prenylation, a specific lipid
modification of proteins that promotes their association with
membranes, is known to be required for the maturation of
infectious hepatitis delta virus (HDV). Co-infection of HDV
with hepatitis B virus (HBV) causes rapid progression to
chronic liver disease. But HDV is a replication-defective
virus that requires the HBV surface antigen to become infec-
tious, and the acquisition of this antigen depends on the
HDV large delta antigen, a protein that has a prenylation
motif recognized by the enzyme farnesyltransferase.
Inhibitors of farnesyltransferase have been developed to
prevent prenylation of Ras and the subsequent association of
Ras with membranes, thereby reducing its transforming
properties. Bordier et al. [18,19] have shown that farnesyl-
transferase inhibitors reduced HDV infectious virion pro-
duction [18] and also reduced HDV viral load, as assessed by
the number of viral RNA copies in the serum of an experi-
mental mouse model for HDV liver infection [19]. This raises
the important possibility that prenylation inhibitors, which
are known to have low side effects, could be a new class of
antiviral agents [25]. 
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Table 1
Host drug targets that have antiviral activity
Antiviral Antiviral
activity activity
Virus family Virus species Host-cell target Drug in vitro in vivo References
Poxviridae Vaccinia virus Abl tyrosine kinase Gleevec + + [13]
Herpesviridae KSHV c-Kit Gleevec + + [14,21]
KSHV Vitamin D receptor Vitamin D  + - [16]
analog EB1089
HSV-1 EIF-2 Salubrinal + - [30]
HCMV COX-2 BMS-279652 + - [15,23]
BMS-279654
BMS-279655
Indomethacin
Aspirin
Unclassified Hepatitis D virus Farnesyltransferase FTI-277 + + [18,19]
FTI-2153
Hepadnaviridae Hepatitis B virus Heterogeneous nuclear   siRNA + - [31]
ribonucleoprotein K (hnRNP K)
Retroviridae HIV HMG-CoA reductase Lovastatin + + [17]
HIV Geranylgeranyltransferase I GGTI-286 + - [17]
` HIV ATM kinase KU-55933 + - [28]
HIV Deoxyhypusine synthase CNI-1493 + - [29]
HIV Histone deacetylase Valporic acid + + [32,33]
Flaviviridae West Nile disease virus c-Yes (Src family kinases) PP2 + - [20]
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Figure 1 (see legend on the following page)
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Applying to HIV infections the approach of looking for known
drugs that also affect viruses has resulted in new potential
treatment options. The upregulation of genes involved in cho-
lesterol biosynthesis pathways has been observed by gene-
expression studies of HIV-infected cells in vitro. The
upregulation increases the cellular levels of cholesterol, an
effect mediated by the HIV protein Nef [26,27]. Cholesterol-
lowering drugs such as statins, which inhibit 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-limiting
enzyme in the cholesterol biosynthetic pathway, might
therefore have an antiviral effect on HIV. 
In a ground breaking study, del Real et al. [17] tested the
effect of statins on HIV replication both in vitro and in vivo.
Amazingly, statins both inhibited HIV replication in culture,
an effect that could be reversed by bypassing HMG-CoA
reductase by adding the enzyme’s product mevalonate (see
Figure 1), and reduced HIV viral load by greater than three-
fold in six patients treated for one month. Interestingly, del
Real et al. [17] showed that the anti-HIV effect of the statins
was mediated by geranylgeranyl pyrophosphate, the other
prenyl lipid involved in prenylating proteins. Inhibition of
geranylgeranyltransferase I with a small-molecule inhibitor
recapitulated the anti-HIV effect of the statin, whereas far-
nesyltransferase inhibitors had no effect. Geranylgeranyla-
tion is required for post-translational modification of Rho
GTPases, and the HIV envelope protein activates Rho upon
binding the cell surface; it is therefore possible that the anti-
HIV effects of statins occur through disruption of Rho acti-
vation, required for efficient virus entry into the cell, that is
induced by the HIV envelope protein gp120 [17].
HIV replication can also be inhibited by targeting other cellu-
lar functions. Several studies have shown that the cellular
mechanisms responsible for repairing DNA double-strand
breaks are required to support retroviral infection and
prevent cell death. Lau et al. [28] demonstrated that the
ataxia-telangiectasia (ATM) kinase, one of the cellular regula-
tors of responses to DNA damage, is activated by integration
of the HIV genome into the host-cell genome. Inhibiting ATM
kinase activity efficiently blocked HIV replication in T cells by
inducing cell death in the infected cells, most probably as a
result of an impaired ability to repair DNA double-stranded
breaks arising from retroviral genome integration. Inhibiting
ATM kinase also worked synergistically with existing anti-
retroviral drugs [28]. 
By a similar rationale, Hauber et al. [29] used knowledge
about the HIV Rev protein to identify a novel antiviral
agent: Rev uses the eukaryotic initiation factor 5A (eIF-5a)
as a cofactor for the nuclear export of unspliced viral RNAs
containing the Rev-responsive element. Activity is con-
ferred on eIF-5a by the modification of the amino acid
lysine to hypusine. The catalysis of the hypusine modifica-
tion is achieved by two enzymes, deoxyhypusine synthase
(DHS) and deoxyhypusine hydrolase. A small-molecule
inhibitor of DHS, CNI-1493, is known to have antiprolifera-
tive effects on human cells in vitro and is currently being
assessed clinically for the treatment of Crohn’s disease.
Hauber et al. [29] showed that CNI-1493 could inhibit HIV
replication in vitro at drug concentrations below those that
are being used in the clinical trials, suggesting that CNI-
1493 is also a potential antiviral.
Inhibition of basic host-cell functions  
Targeting aspects of the host mRNA transport and translation
initiation mechanisms are also ways of inhibiting herpes
simplex virus (HSV) and HBV replication. Research aimed at
protecting cells from endoplasmic reticulum (ER) stress
showed that the small molecule salubrinal could block dephos-
phorylation of the eukaryotic initiation factor eIF-2, and that
this inhibited HSV replication. All eukaryotic cells respond to
ER stress, including the stress induced by viral infection, by
inducing a set of pathways known collectively as the unfolded
protein response. The unfolded protein response leads in part
to the phosphorylation of eIF-2 and subsequent transient
translational arrest, a cytoprotective response. Virus infection
can also induce eIF-2 phosphorylation through the double-
stranded RNA-activated protein kinase (PKR). To counteract
this activity HSV encodes a protein (ICP34.5) that interacts
with cellular proteins to mediate eIF-2 dephosphorylation. 
Testing of salubrinal in an HSV-infection assay showed that
the small molecule could block HSV-mediated eIF-2 dephos-
phorylation and prevent HSV replication [30]. Similarly,
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Figure 1 (see figure on the previous page)
Well characterized drugs that inhibit prenylation can also be used to inhibit viruses. The biosynthetic pathway from acetyl CoA to squalene and then on
through multiple other steps (not shown) to ubiquinone, cholesterol and dolichol is shown. Statins inhibit HMG-CoA reductase and thereby prevent the
synthesis of mevalonate and subsequent downstream lipids; statins also inhibit the replication of HIV [17]. Farnesyl pyrophosphate and geranyl
pyrophosphate are the substrates for farnesyltransferase and geranylgeranyltransferase I and II, respectively. These enzymes catalyze the prenylation of
proteins (blue hexagons), with farnesyltransferase catalyzing the addition of the 15-carbon farnesyl prenyl lipids to the cysteine of the tetrapeptide CXXX
(where X is one of a possible three amino acids at the carboxyl terminus of the protein) and geranylgeranyltransferase I and II catalyzing the addition of
20-carbon geranyl prenyl lipids to CXXX, CC or CXC motifs. Farnesyltransferase inhibitors (FTI) block the farnesylation of proteins such as Ras and also
inhibit the replication of hepatitis delta virus (HDV) [18,19]. Similarly, geranylgeranyltransferase inhibitors (GGTI) block the geranylation of proteins such
as Rho and also inhibit the replication of HIV [17]. The prenylation of Ras and Rho proteins promotes their association with membranes and is therefore
necessary for the targeting of these proteins to the plasma membrane, where they function.knowledge that the HBV genome enhancer region binds het-
erogeneous nuclear ribonucleoprotein K (hnRNP K), a pre-
mRNA-binding protein that shuttles between the nucleus
and cytoplasm, led Ng et al. [31] to remove hnRNP K using
RNA interference (RNAi) gene silencing and to demonstrate
that this reduces HBV DNA replication by up to 50%.
The ability to target host-cell proteins as antivirals is not
limited to DNA viruses (poxviruses and herpesviruses) or
viruses that use DNA intermediates as part of their replica-
tive life cycle (hepadnaviruses and retroviruses). Studies of
gene-expression changes caused by infection with West Nile
virus (WNV), a flavivirus the genome of which consists of a
single-stranded positive-sense RNA molecule, showed that
the gene encoding the Src-family kinase (SFK) c-Yes was
upregulated fivefold [20]. Specifically inhibiting SFKs with
small molecules and removing c-Yes by RNAi significantly
inhibited WNV replication in vitro [20]. 
Treating persistent virus infections 
Many viruses, especially herpesviruses and retroviruses,
persist for the lifetime of the host after the initial infec-
tion. These ‘latent’ infections are the source of continued
virus production, but they are generally not affected by
the range of drugs that target the lytic side of the viral life
cycle. Recently, the prospect of using licensed drugs to
deplete latently HIV-infected cells in patients has shown
promising results. 
Histone deacetylase 1 (HDAC1), which mediates chromatin
remodeling, has been implicated in the repression of HIV
gene expression in infected cells, and inhibition of HDAC1
by the anticonvulsant valporic acid (VPA) results in reacti-
vation of HIV-1 replication in latently infected T cells [32].
This may seem like a bad effect, but it raises the possibility
of using VPA to induce a ‘flushing out’ of latently infected
cells in combination with antiretroviral drugs to prevent
infection of new cells. The idea was tested in a small group
of patients, and the combination of VPA and the antiretrovi-
ral enfuvirtide resulted in a significant decline in latently
infected resting T cells [33]. It may therefore be possible in
the future to reactivate latent virus infections in a con-
trolled way and thereby perhaps eliminate the virus from
the individual completely. 
Systematic hunting for new antiviral targets 
Together, the approaches described above provide sufficient
evidence that targeting host-cell processes is a good
approach to finding new antiviral drugs. More of the same
kind of research will clearly uncover other cell processes that
can be similarly inhibited. Fewer than half of the studies dis-
cussed so far, however, used DNA microarray technology to
provide the first clue to which drug to use [14-16,20], sug-
gesting that greater use of unbiased approaches will uncover
a greater range of novel drug targets. 
The use of genomics and bioinformatics in drug discovery is
now part of the core business of many pharmaceutical com-
panies [34,35]. This has resulted in a rationalization of the
sort of data required and how they are integrated to facilitate
discovery of new drugs. The simplest unbiased approach to
finding new antivirals would be to assess systematically the
gene-expression changes induced in appropriate target cells
by a range of viruses, and then link the induced genes to
known drugs that target the protein or pathway encoded by
the induced genes. This can be undertaken in vitro, as the data
generated from appropriate cells seem to be robust and can be
translated directly into therapies for patients [17,21,33]. 
As it is unlikely that one laboratory will generate all possible
virus-induced host gene-expression data, it is clear that data
sharing and integration will be required, an idea champi-
oned by the Katze laboratory through their view of a ‘virus
compendium’ to capture such information [36]. If such a
compendium were integrated with data on existing drugs
and their protein or pathway targets, we would have an
easily accessible means of finding potential antivirals. Even
in the absence of a unified compendium, meta-analysis of
host gene-expression programs altered by infection has
revealed over 500 genes that can now be explored [9]. If
these are not direct targets themselves, the clever use of
‘pathway expansion’ methods should reveal alternative pro-
teins that could be used to achieve an antiviral effect.
Pathway expansion allows a given protein (which may or
may not be the target of an existing drug) to be placed in a
functional pathway, thereby identifying additional pathway
proteins as potential drug targets. When unraveling the anti-
HIV effects of statins, knowledge that HMG-CoA reductase
is part of the pathway producing farnesyl and geranyl
pyrophosphate (see Figure 1) allowed the identification of
farnesyl- and geranyltransferase inhibitors as additional
drugs in the expanded pathway [17]. 
To find more general targets, this strategy could be integrated
with high-throughput loss-of-function assays, in which the
function being assessed is the ability of the cells to support
viral replication. This could be undertaken either in model
systems or in cell types that can actually be infected by the
viruses of interest. The idea of using model systems stems
from the work of two groups [37-39], who assessed yeast
single-gene-deletion libraries for their ability to support the
replication of RNA virus genomes. Each study identified a
range of yeast genes that were required for viral-genome
replication or recombination. A concern must be raised about
the low level of concordance between genes identified by the
two groups, however. In fact, comparing genes required for
tomato bushy stunt virus (TBSV) replication with those for
brome mosaic virus (BMV) replication identified only four
genes needed for both viruses. This small overlap can be
explained in part by different experimental systems and the
fact that TBSV and BMV represent different supergroups of
viruses. Nevertheless, the real proof that these surrogate
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inhibiting some of the genes in real viral replication systems. 
A more authentic method, and one supported by some of the
examples described above, would be the large-scale loss-of-
function screening of human cells with RNAi libraries [40].
When combined with expression vectors to produce short
interfering RNAs (siRNAs), such screens have been success-
ful in identifying new modulators of the proliferation arrest
that is dependent on the transcription factor p53 [41]. 
A related method of using genetic suppressor elements has
been used in the context of HIV infection. Genetic suppres-
sor elements work by blocking target-gene function through
an inhibitory RNA or the production of trans-dominant pep-
tides. When used to screen for genes important for HIV
infection, this method revealed known proteins, such as the
chemokine receptor CXCR4 and cyclin T1, together with
additional proteins that were subsequently confirmed to
affect HIV replication [42]. Such approaches could identify
many important host-cell factors, but care will be needed to
exclude the possibility that they do not induce an apparent
antiviral response by simply activating classical cellular
sensors of viral infection, such as PKR.
Combined with existing mechanistic insights into host-
pathogen interactions, the coordinated use of unbiased,
large-scale genomic methods will reveal a richer picture of
the integrated host-cell response to infection and could well
unlock the largely untapped potential of inhibiting virus
replication through targeting the host. Whether using exist-
ing drugs in an infectious disease setting will result in addi-
tional side effects is not known, but the safety profiles of
drugs generated from their current clinical use suggest that
this will not be a large concern. The use of existing drugs for
a new antiviral purpose, although in some cases not as effec-
tive as traditional antiviral drugs in preventing virus replica-
tion, will also enable combination therapies and may be less
likely to cause selection for drug-resistant viruses. 
In conclusion, the constraints on developing drugs to treat
diseases caused by the wide variety of microbes has left us
with a gap in healthcare that existing and emerging
pathogens can all too easily colonize. The potential to target
host-cell functions that prevent or reduce pathogen replica-
tion may be a quick and cost-effective way to plug this gap.
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